Lecture: Gene Therapy for AMD: Are We There Yet?

During this live webinar, we will discuss the concept of retinal gene therapy and its use for rare and common diseases, and how the type of vector, viral dose, and mode of delivery dictate efficacy and safety in both preclinical and clinical studies. We will also discuss ocular immune privilege, the impact of biological barriers, and factors that determine the degree of ocular inflammation related to gene therapy – also known as gene therapy-associated uveitis (GTAU). Finally, we will review gene therapy programs in development for age-related macular degeneration (AMD), as well as early studies using CRISPR-based gene editing technology as potential treatments for AMD. (Level: Beginner and Intermediate)

Lecturer: Dr. Glenn Yiu, Ophthalmologist, University of California, Davis, USA